- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02855476
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease (HDClarity)
Study Overview
Status
Conditions
Detailed Description
This is a longitudinal open-ended observational study. Participants will attend two annual study visits, an Annual Screening Visit followed by an Annual Sampling Visit, and may also attend an optional visit during the first year of enrollment, an Optional Repeat Sampling Visit.
During the Annual Screening Visit, medical history, and clinical and phenotypic data will be obtained. Participants who meet the eligibility requirements of the study and are willing to continue in the study, will return for an Annual Sampling Visit. During that visit, biosamples will be collected following a fast of at least 6 hours, or overnight: blood will be obtained via venipuncture and CSF will be obtained via lumbar puncture. Some participants may be invited to return for an Optional Repeat Sampling Visit approximately 4-8 weeks after the Annual Sampling Visit during their first year of enrolment.
The annual visits are at regular intervals after the first Annual Screening Visit (i.e. at 1, 2, 3 years and so on) ± 2 months. Participants will be encouraged to complete all annual visits; however, they are under no obligation to take part and will be able to skip annual visit without being discontinued from the study. Participants who do not come for an Annual Sampling Visit for three consecutive years will be discontinued from the study, but they may enrol again at a later date, if they so consent. Participants who have already completed HDClarity Sampling Visits under earlier versions of this protocol may also participate in the longitudinal study if they meet the eligibility criteria.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Katarzyna Schubert, PhD
- Email: hdclarity-cc@enroll-hd.org
Study Contact Backup
- Name: Gail Owen, PhD
- Phone Number: +44 1273 640 688
- Email: g.owen@ucl.ac.uk
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6T 2B5
- Recruiting
- University of British Columbia, The Centre for Huntingtons Disease
-
Contact:
- Mike Adurogbangba
- Phone Number: 604-822-4872
- Email: madurogbangba@cmmt.ubc.ca
-
Principal Investigator:
- Blair Leavitt, MD, CM
-
-
Ontario
-
Ottawa, Ontario, Canada, K1Y 4E9
- Recruiting
- The Ottawa Hospital
-
Contact:
- Jane Ding
- Email: jading@toh.ca
-
Principal Investigator:
- Tiago Mestre, Dr
-
Toronto, Ontario, Canada, M2K 1E1
- Recruiting
- North York General Hospital
-
Contact:
- Rebecca Solmito
- Email: Rebecca.Solmito@nygh.on.ca
-
Principal Investigator:
- Philippe Rizek, Dr
-
Toronto, Ontario, Canada, M3B 2S7
- Completed
- Centre for Movement Disorders
-
-
-
-
-
Bochum, Germany, 44791
- Recruiting
- St Josef And Elisabeth Hospital
-
Principal Investigator:
- Carsten Saft
-
Contact:
- Barbara Kaminski
- Email: b.kaminski@klinikum-bochum.de
-
Erlangen, Germany, 91054
- Recruiting
- University Hospital of Erlangen
-
Principal Investigator:
- Winkler Jurgen
-
Contact:
- Susanne Seifert
- Phone Number: 09131-85-44751
- Email: susanne.seifert@uk-erlangen.de
-
Münster, Germany, 48149
- Recruiting
- George Huntington Institute
-
Principal Investigator:
- Ralf Reilmann
-
Contact:
- Svenja Aufenberg
- Phone Number: +49-251-788-788-0
- Email: svenja.aufenberg@ghi-muenster.de
-
-
Baden-Württemberg
-
Ulm, Baden-Württemberg, Germany, 89081
- Recruiting
- University Hospital Ulm
-
Contact:
- Hela Jerbi
- Phone Number: +49 731-500-63080
- Email: hela.jerbi@uniklinik-ulm.de
-
Principal Investigator:
- Jan Lewerenz, MD
-
-
Saxony
-
Dresden, Saxony, Germany, 01307
- Recruiting
- Dresden University
-
Contact:
- Simone Koegler
- Phone Number: 351- 458 2524
- Email: simone.koegler@uniklinikum-dresden.de
-
Principal Investigator:
- Bjoern Falkerburger, MD
-
-
-
-
-
Milan, Italy, 20133
- Active, not recruiting
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
-
Rome, Italy, 00185
- Recruiting
- Lega Italiana Ricera Huntington
-
Contact:
- Consuelo Ceccarelli
- Email: consuelo.ceccarelli@lirh.it
-
Principal Investigator:
- Ferdinando Squitieri, MD
-
-
-
-
Canterbury
-
Christchurch, Canterbury, New Zealand, 8011
- Recruiting
- NZ Brain Research Institute
-
Contact:
- Laura Paermentier
- Email: Laura.Paermentier@cdhb.health.nz
-
Principal Investigator:
- Tim Anderson, Prof
-
-
-
-
-
Warsaw, Poland, 02-957
- Active, not recruiting
- Institute of Psychiatry and Neurology
-
-
-
-
-
Barcelona, Spain, 08041
- Recruiting
- Hospital de Sant Pau
-
Contact:
- Cristina Barrionuevo
- Phone Number: +34 649 14 23 60
- Email: CIzquierdo@santpau.cat
-
Principal Investigator:
- Jamie Kulisevsky, MD, PhD
-
-
Biscay
-
Bilbao, Biscay, Spain, 48903
- Recruiting
- Cruces University Hospital
-
Contact:
- Marian Ángeles Acera Gil
- Email: M.ANGELES.ACERAGIL@osakidetza.eus
-
Principal Investigator:
- Tamara Fernandez Valle, Dr
-
-
-
-
-
Bristol, United Kingdom, BS10 5NB
- Not yet recruiting
- North Bristol NHS Trust
-
Contact:
- Catherine Watkins
- Email: catherine.watkins@nbt.nhs.uk
-
Principal Investigator:
- Elizabeth Coulthard, MBBS
-
Cambridge, United Kingdom, CB2 0PY
- Recruiting
- Cambridge University Hospitals NHS Foundation Trust
-
Principal Investigator:
- Roger Barker
-
Contact:
- Katie Andresen
- Phone Number: 01223 331141
- Email: kera2@cam.ac.uk
-
Cardiff, United Kingdom, CF24 4HQ
- Recruiting
- Cardiff University
-
Contact:
- Alison Johnson
- Phone Number: 02920746394
- Email: alison.johnson@wales.nhs.uk
-
Principal Investigator:
- Anne Rosser, MD
-
Kirkcaldy, United Kingdom, KY1 2ND
- Active, not recruiting
- Fife Health Board - Whyteman's Brae Hospital
-
Leeds, United Kingdom, LS7 4SA
- Recruiting
- Leeds Teaching Hospital Trust
-
Contact:
- Callum Schofield
- Phone Number: 0113 39 24679
- Email: callum.schofield@nhs.net
-
Principal Investigator:
- Jeremy Cosgrove, MBBS
-
Liverpool, United Kingdom, L9 7LJ
- Active, not recruiting
- The Walton Centre NHS Foundation Trust
-
London, United Kingdom, NW1 2PG
- Recruiting
- University College London Hospitals NHS Foundation Trust
-
Contact:
- Fiona Kinsella
- Phone Number: 0203 108 2638
- Email: fiona.kinsella.19@ucl.ac.uk
-
Principal Investigator:
- Edward Wild, MD, PhD
-
London, United Kingdom, SW17 0RE
- Recruiting
- St George's University of London
-
Principal Investigator:
- Nayana Lahiri
-
Contact:
- Sally Goff
- Phone Number: 0208 725 5375
- Email: sally.goff@nihr.ac.uk
-
Oxford, United Kingdom, OX3 9DU
- Recruiting
- Oxford University Hospitals NHS Foundation Trust
-
Contact:
- Zara Skitt
- Phone Number: 01865 234309
- Email: zara.skitt@ouh.nhs.uk
-
Principal Investigator:
- Richard Armstrong, MA, PhD, BMBCh, MRCP
-
Plymouth, United Kingdom, PL6 5FP
- Active, not recruiting
- University Hospitals Plymouth NHS Trust
-
-
Devon
-
Exeter, Devon, United Kingdom, EX2 5DW
- Recruiting
- Royal Devon & Exeter NHS Foundation Trust
-
Contact:
- Robert Wells
- Phone Number: 01392408181
- Email: Robert.wells2@nhs.net
-
Principal Investigator:
- Tim Harrower, MBBS
-
-
Scotland
-
Glasgow, Scotland, United Kingdom, G51 4TF
- Recruiting
- Glasgow Clinical Research Facility
-
Contact:
- Helen Bannister
- Phone Number: 0141 232 7600
- Email: helen.bannister@ggc.scot.nhs.uk
-
Principal Investigator:
- Matthew Sheridan, MBBS
-
-
West Midlands
-
Birmingham, West Midlands, United Kingdom, B15 2 FG
- Recruiting
- Birmingham Huntingtons Disease Clinic
-
Contact:
- Jennifer De Souza
- Phone Number: 0121 301 2363
- Email: jennifer.desouza@bsmhft.nhs.uk
-
Principal Investigator:
- Hugh Rickards, MB, ChB, MSc, FRCPsych, MD
-
-
-
-
Colorado
-
Englewood, Colorado, United States
- Recruiting
- CenExel
-
Principal Investigator:
- Rajeev Kumar, MD
-
Contact:
- Jessica Crall
- Phone Number: 303-867-5473
- Email: j.crall@cenexel.com
-
Contact:
- Melanie Patton
- Email: m.patton@cenexel.com
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20057
- Recruiting
- Georgetown University
-
Contact:
- Erin Koppel
- Phone Number: 202-687-1525
- Email: ek875@georgetown.edu
-
Principal Investigator:
- Karen Anderson, MD
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Recruiting
- John Hopkins University
-
Contact:
- Kia Ultz
- Phone Number: 410-955-1349
- Email: kcarte23@jhmi.edu
-
Principal Investigator:
- Jee Bang, MPH, MD
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27109
- Active, not recruiting
- Wake Forest University
-
-
Tennessee
-
Nashville, Tennessee, United States, 37212
- Recruiting
- Vanderbilt University Medical Center
-
Contact:
- Elizabeth Huitz, RN
- Phone Number: 615-936-1007
- Email: elizabeth.huitz@vumc.org
-
Principal Investigator:
- Daniel Claassen, MD, MS
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- University of Texas Health Science Center
-
Contact:
- Brittany Duncan
- Phone Number: 713-486-3134
- Email: brittany.j.duncan@uth.tmc.edu
-
Principal Investigator:
- Erin Furr-Stimming
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age (18-75 years controls, early/late premanifest HD and incomplete penetrance HD, 21-75 years early/moderate/advanced manifest HD, ≥11 years juvenile HD)
- Enroll HD participant
- Capable of consenting or have a legal representative (parent/guardian for juveniles)
- Capable of complying with study procedures
- All participants other than family and community controls must have had a genetic test for HD
Exclusion Criteria:
- Drug trial within 30 days of any sampling visit
- Changes in medication (antidepressant, psychoactive, psychotropic or other medications or nutraceuticals used to treat HD within 30 days)
- Antiplatelet or anticoagulant therapy within 14 days
- Significant comorbidity
- Needle phobia, headache, spinal surgery / deformity
- Clotting or bruising disorder
- Screening blood test abnormalities >10% outside normal range
- Drug / alcohol abuse
- Positive urine pregnancy test at any screening or sampling visit for females of childbearing potential
- Predictable non compliance or unwillingness
- Serious adverse event related to HDClarity study procedures or any lumbar puncture procedure performed for any reason in the previous 30 days
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Early Pre-manifest HD
Participants eligible are persons who meet the following criteria:
|
Late Pre-manifest HD
Participants eligible are persons who meet the following criteria:
|
Early Manifest HD
Participants eligible are persons who meet the following criteria:
|
Moderate Manifest HD
Participants eligible are persons who meet the following criteria:
|
Advanced Manifest HD
Participants eligible are persons who meet the following criteria:
|
Incomplete Penetrance HD
Participants eligible are persons who meet the following criteria:
|
Juvenile Manifest HD
Participants eligible are persons who meet the following criteria:
|
Healthy Control
Participants eligible are persons who meet the following criteria:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary objective of this study is:
Time Frame: years N/A
|
To generate a high quality CSF sample collection for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD.
|
years N/A
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The secondary objectives of this study are:
Time Frame: years N/A
|
To generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development. To collect phenotypic and clinical data for each participant. |
years N/A
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Edward J Wild, MA, MB BChir, MRCP, PhD, University College, London
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Genetic Diseases, Inborn
- Basal Ganglia Diseases
- Movement Disorders
- Neurodegenerative Diseases
- Dyskinesias
- Heredodegenerative Disorders, Nervous System
- Dementia
- Cognition Disorders
- Chorea
- Huntington Disease
Other Study ID Numbers
- 15/0519
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Study Data/Documents
- Study Protocol
-
Informed Consent Form
Information comments: Draft informed consent form, not yet approved by an Institutional Review Board for clinical use
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Huntington's Disease
-
Massachusetts General HospitalCompletedHuntington's Disease (HD)United States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
SOM Innovation Biotech SACompleted
-
Sanguine BiosciencesHoffmann-La RocheRecruitingHuntington Disease | Huntington's Dementia | Huntington Disease, Late Onset | Huntington; Dementia (Etiology)United States
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
-
PfizerMedivation, Inc.CompletedAlzheimer's Disease | Huntington's DiseaseUnited States
-
PfizerMedivation, Inc.CompletedHuntington Disease | Alzheimer's DiseaseUnited States
-
Hoffmann-La RocheCompleted
-
PfizerMedivation, Inc.CompletedAlzheimer's Disease | Huntington's DiseaseUnited States
-
PfizerMedivation, Inc.CompletedAlzheimer's Disease | Huntington's DiseaseUnited States